参考文献/References:
[1] Alenazy FO,Thomas MR. Novel antiplatelet targets in the treatment of acute coronary syndromese[J].?Platelets,2021,32(1):15-28.
[2] Wang L,Cong HL,Zhang JX,et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome[J].?Cardiovasc Diabetol,2020,19(1):80.
[3] Kim YH,Her AY,Jeong MH,et al. Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients [J].?Sci Rep,2021,11(1):9364.
[4] Deedwania P,Acharya T,Kotak K,et al. Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome:findings from the American Heart Association’s Get With The Guidelines-Coronary Artery Disease(GWTG-CAD) program[J].?Am Heart J,2017,187:78-87.
[5] Viswanathan GN,Marshall SM,Balasubramaniam K,et al. Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome[J].?Thromb Res,2014,133(5):880-885.
[6] Angiolillo DJ,Badimon JJ,Saucedo JF,et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease:results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial[J].?Eur Heart J,2011,32(7):838-846.
[7] Feng WH,Chang YC,Lin YH,et al . Comparative efficacy and safety of P2Y12 inhibitor monotherapy and dual antiplatelet therapy in patients with and without diabetes mellitus undergoing percutaneous coronary i ntervention[J].?Int J Mol Sci,2022,23(9):4549.
[8] Imam H,Nguyen TH,de Caterina R,et al. Impaired adenylate cyclase signaling in acute myocardial ischemia:impact on effectiveness of P2Y12?receptor antagonists[J].?Thromb Res,2019,181:92-98.
[9] Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment[J].?Diabetes,2005,54(8):2430-2435.
[10] 沈迎,丁风华,张瑞岩,等. 高龄老年(≥75岁)急性冠状动脉综合征患者规范化诊疗中国专家共识解读[J]. 中国循环杂志,2019,34(z1):13-17.
[11] Angiolillo DJ,Jakubowski JA,Ferreiro JL,et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease[J]. J Am Coll Cardiol ,2014,64(10):1005-1014.
[12] Pereira NL,Rihal CS,So DYF,et al. Clopidogrel pharmacogenetics[J].?Circ Cardiovasc Interv,2019,12(4):e007811.
[13] Nardin M,Verdoia M,Sartori C,et al. Diabetes mellitus,glucose control parameters and platelet reactivity in ticagrelor treated patients [J].?Thromb Res,2016,143:45-49.
[14] Verdoia M,Pergolini P,Nardin M,et al. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation [J].?J Cardiol,2019,73(3):198-203.
[15] 中国医师协会心血管内科医师分会血栓防治 专业委员会,中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会. 急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议[J]. 中华心血管病杂志,2018,46(4):255-266.
[16] Chen WWC, Law KK, Li SK, et al. Extended dual antiplatelet therapy for Asian patients with acute coronary syndrome:expert recommendations[J].?Intern Med J,2019, 49(suppl 1):5-8.
[17] Cavallari I,Maddaloni E,Gragnano F,et al. Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome[J].?Intern Emerg Med,2021,16(6):1583-1591.
[18] He P,Luo X,Li J,et al. Clinical outcome between ticagrelor versus clopidogrel in patients with acute coronary syndrome and diabetes [J].?Cardiovasc Ther,2021,2021:5546260.
[19] Park DW,Kwon O,Jang JS,et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management:a randomized clinical trial[J].?Circulation,2019,140(23):1865-1877.
[20] Chen S,Li J,Qiu M,et al. Predictors and long-term outcomes of in-hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention[J].?Catheter Cardiovasc Interv,2022,99(suppl 1):1424-1431.
[21] Franchi F,James SK,Ghukasyan Lakic T,et al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12receptor antagonist effects in patients with acute coronary syndromes:insights from the PLATO trial[J].?J Am Heart Assoc,2019,8(6):e011139.
[22] Li D,Sun Y,Ye X,et al. Comparison of net clinical benefit between clopidogrel and ticagrelor following percutaneous coronary intervention in patients in China with acute coronary syndrome[J]. Adv Ther,2022,39(1):754-766.
[23] Gil-Perez P,Ruiz-Nodar JM,Esteve-Pastor MA,et al. Clinical implications of diabetes mellitus in patients with acute coronary syndrome:prognostic role and use of new P2Y12?receptor inhibitors[J].?Diabetes Res Clin Pract,2022,184:109215.
[24] Conrotto F,Bertaina M,Raposeiras-Roubin S,et al. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes:a propensity matched substudy of RENAMI[J].?Eur Heart J Acute Cardiovasc Care,2019,8(6):536-542.
[25] Ndrepepa G,Kastrati A,Menichelli M,et al. Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetesmellitus[J].?JACC Cardiovasc Interv,2020,13(19):2238-2247.
[26] An K,Guo P,Qiu S,et al. Optimal duration of dual antiplatelet therapy followed by monotherapy in diabetic patients after percutaneous coronary intervention with drugeluting stent implantation:a Bayesian network meta-analysis[J].?Pol Arch Intern Med,2021,131(9):781-789.
[27] Liang XY,Li Y,Qiao X,et al. Clinical outcomes of very short term dual antiplatelet therapy in patients with or without diabetes undergoing second-generation drug-eluting stents:a systematic review and meta-analysis of randomized clinical trials [J].?Front Cardiovasc Med,2021,8:655718.
[28] Lee SJ,Choi DW,Kim C,et al. Prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with diabetes mellitus:a nationwide retrospective cohort study[J].?Front Cardiovasc Med ,2022,9:954704.
[29] Wang W,Wang X,Zhang L,et al. Treatment outcomes of clopidogrel in patients with ACS and diabetes undergoing PCI—Analysis of Beijing Municipal Medical Insurance Database[J].?Front Endocrinol(Lausanne),2021,12:713849.
[30] Obayashi Y,Watanabe H,Morimoto T,et al. Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention:from the STOPDAPT-2 total cohort[J].?Circ Cardiovasc Interv,2022,15(8):e012004.
[31] Watanabe H,Morimoto T,Natsuaki M,et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome:the STOPDAPT-2 ACS randomized clinical trial [J].?JAMA Cardiol,2022,7(4):407-417.
[32] Angiolillo DJ,Baber U,Sartori S,et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention[J].?J Am Coll Cardiol,2020,75(19):2403-2413.
[33] Gamal AS,Hara H,Tomaniak M,et al. ‘Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI’:a post hoc analysis of the randomized GLOBAL LEADERS trial[J].?Eur Heart J Acute Cardiovasc Care,2021,10(7):756-773.
相似文献/References:
[1]张若愚,综述,殷跃辉,等.2型糖尿病及其药物对心房颤动的影响[J].心血管病学进展,2016,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
ZHANG Ruoyu,YIN Yuehui.Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
[2]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[3]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[4]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[5]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(7):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[6]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(7):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[7]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(7):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[8]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(7):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[9]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(7):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[10]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(7):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[11]叶滔 童琳 崔彩艳 成联超 童兰 蔡琳.残余胆固醇对急性冠脉综合征合并/不合并糖尿病患者远期预后的影响[J].心血管病学进展,2024,(8):762.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.019]
YE Tao,TONG Lin,CUI Caiyan,et al.Effect of Residual Cholesterol on Long-Term Prognosis in Patients with Acute Coronary Syndrome with or without Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2024,(7):762.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.019]